News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phage Pharmaceuticals (Formerly Known as Phage Biotechnology Corp.) to File Investigational New Drug (IND) Application Using Its Lead Drug Candidate, FGF-1, for a First-in-Class Indication to Repair Tympanic Membrane Perforations



12/21/2011 6:03:25 AM

SAN DIEGO--(BUSINESS WIRE)--Phage Pharmaceuticals, a private biopharmaceutical company based in San Diego, California, announced today the submission of an IND to the US FDA to initiate a Phase 1 clinical trial of its FGF-1 drug for the repair of tympanic membrane perforations.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES